<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061487</url>
  </required_header>
  <id_info>
    <org_study_id>ER.ALL.2016.04</org_study_id>
    <nct_id>NCT03061487</nct_id>
  </id_info>
  <brief_title>Influence of Statins in Artery Aneurysms</brief_title>
  <acronym>INSTANT</acronym>
  <official_title>The Influence of Statin Treatment on Aneurysmatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cantanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cantanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The altered balance between the proteinases and their tissue inhibitors (TIMPS) is one of the
      pathogenetical mechanism of the aneurysmatic connective tissue degeneration. The increasement
      of protease, collagenase and elastase activity results indeed in a dramatic drop of collagen
      and elastin tissue and serum levels.Matrix Metalloproteinases (MMPs) are a group of
      proteolytic enzymes that along with their specific and non-specific inhibitors modulate the
      extracellular matrix composition. Recent studies have suggested an interesting role of
      microRNAs (miRNAs) in the regulation mechanisms of inflammation.

      The aim of our study is to analyse the influence of statin treatment on aneurysmatic disease
      by monitoring MMPs and miRNAs in aneurysmatic wall tissue and MMps blood levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The altered balance between the proteinases and their tissue inhibitors (TIMPS) is one of the
      pathogenetical mechanism of the aneurysmal connective tissue degeneration. The increase of
      protease, collagenase and elastase activity results indeed in a dramatic drop of collagen and
      elastin tissue and serum levels.

      Vessels wall strength decrease is associated with the blood flow shear stress and affects
      negatively the walls integrity, causing the aneurysmatic vessel degeneration.

      Matrix Metalloproteinases (MMPs) are a group of proteolytic enzymes that along with their
      specific and non-specific inhibitors modulate the extracellular matrix composition.

      So far, 25 MMPs have been discovered, in particular, the ones that will be considered in this
      study are: MMP-2, MMP-9, and neutrophil gelatinase-associated lipocalin (NGAL) a related
      protein which is able to control MMP-9 activities.

      Inflammation plays a central role in the pathogenetical pathway of aneurysmatic developement.
      Recent studies have suggested an interesting role of miRNAs in the regulation mechanisms of
      inflammation. miRNAs are short ribonucleic acid molecules usually composed of 20 to 25
      nucleotides that can regulate mRNA transcription and protein translation by targeting the
      3'-untranslated regions (3'-UTR) of target genes. miRNAs are involved in various
      physiological responses and pathological processes. Increasing evidence suggest that miRNAs
      are involved in inflammatory responses. In particular the ones that will be focused on this
      study are: miR-29b, miR-21, miR-181a, miR-150.

      Very often, patients with aneurysmatic disease are under statin treatment. Some Statins
      (Atorvastatin, Simvastatin or Rosuvastatin) with pleiotropic effects may also play a
      protective role by conditioning the progression of the aneurysmatic degeneration.

      The aim of our study is to analyse the influence of statin treatment on aneurysmatic disease
      by monitoring some MMPs and related molecules (MMP-2, MMP-9 and NGAL), miRNAs (the evaluation
      will be performed in aneurysmatic wall tissues and circulating blood levels).

      Patients affected by central and peripheral aneurysmatic disease will be recruited and then
      divided in two groups based on the dosage of the statin treatment: the first group with
      maximum statin daily dose (Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg), the
      second group with minimum statin daily dose. The latter will be defined as the control group.

      Only patients which will fullfill the criteria to undergo surgical treatment will be
      recruited in the study in order to collect biological specimen of the aneurysmatic tissues .

      The investigation consist in:

        -  taking a preoperative blood sample to evaluate the MMPs circulating levels

        -  taking an aneurysmatic vessel wall histological sample with an intraoperative biopsy to
           evaluate the tissue MMPs and miRNAs levels.

      Previously, several studies suggested a role of MMPs (MMP-2 and MMP-9) and miRNAs in
      regulation of aneurysm developement, in particular miR29b, miR-181a, miR-21, miR-150.

      The comparison between MMPs Levels in the study group and in the control group might
      highlight a role for MMPs level as a marker of aneurysmatic disease progression, consequently
      allowing the patient's stratification by analysing the risk of aneurysmatic evolution and
      growth.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">April 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of MMP-2, MMP-9 and NGAL levels in blood and aneurysms tissue</measure>
    <time_frame>1 year</time_frame>
    <description>MMP-2, MMP-9 and NGAL will be studied in both groups. Elisa Testing will be used to analyze the blood samples and Western blot analysis will be used for the tissue samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evalutation of miRNAs levels in blood and aneurysms tissue</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of miRNAs levels (in particular miR29b, miR-181a, miR-21, miR-150) will be studied in both groups. Stem-loop reverse-transcription PCR (RT-qPCR) method will be used for measuring individual microRNAs (miRNAs) in tissue and blood samples.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Statin</condition>
  <condition>Aneurysm</condition>
  <condition>Extracellular Matrix Alteration</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).
Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
The investigation consist in:
taking a preoperative blood sample to evaluate the MMPs circulating levels
taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.
Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
The investigation consist in:
taking a preoperative blood sample to evaluate the MMPs circulating levels
taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Surgical Treatment of Aneurysm (Aneurysmectomy)</intervention_name>
    <description>Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by central and peripheral aneurysmal disease are going to be recruited
        and then divided in two groups based on the dosage of the statin treatment: the first group
        with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40
        mg), the second group with minimum statin daily dose. The latter will be defined as the
        control group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients under statins treatment with pleiotropic effect: Simvastatin, Rosuvastatin,
             Atorvastatin

          -  Patients underwent open aneurysm repair

          -  Age &gt;18

          -  signing informed consent

        Exclusion Criteria:

          -  Patients with chronic diseases such as liver diseases

          -  Pazient whith malignant diseases

          -  Recreational drug intake and alcohol abuse

          -  Intake of statins other than those under study or in combination therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano de Franciscis, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University Magna Graecia of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raffaele Serra, M.D.; Ph.D.</last_name>
    <phone>+39 09613647380</phone>
    <email>rserra@unicz.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luca Gallelli, M.D.; Ph.D.</last_name>
    <phone>+39 0961 3339245656</phone>
    <email>gallelli@unicz.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Magna Graecia of Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Serra, M.D., Ph.D.</last_name>
      <phone>+3909613647380</phone>
      <email>rserra@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Stefano de Franciscis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Gallelli, M.D.; Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Serra R, Grande R, Montemurro R, Butrico L, Cali√≤ FG, Mastrangelo D, Scarcello E, Gallelli L, Buffone G, de Franciscis S. The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms. Surgery. 2015 Jan;157(1):155-62. doi: 10.1016/j.surg.2014.06.008. Epub 2014 Nov 1.</citation>
    <PMID>25444221</PMID>
  </reference>
  <reference>
    <citation>de Franciscis S, Mastroroberto P, Gallelli L, Buffone G, Montemurro R, Serra R. Increased plasma levels of metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in a rare case of multiple artery aneurysm. Ann Vasc Surg. 2013 Nov;27(8):1185.e5-7. doi: 10.1016/j.avsg.2013.01.011. Epub 2013 Aug 26.</citation>
    <PMID>23988549</PMID>
  </reference>
  <reference>
    <citation>Serra R, Volpentesta G, Gallelli L, Grande R, Buffone G, Lavano A, de Franciscis S. Metalloproteinase-9 and neutrophil gelatinase-associated lipocalin plasma and tissue levels evaluation in middle cerebral artery aneurysms. Br J Neurosurg. 2014 May 5. [Epub ahead of print]</citation>
    <PMID>24799278</PMID>
  </reference>
  <reference>
    <citation>Piechota-Polanczyk A, Demyanets S, Mittlboeck M, Hofmann M, Domenig CM, Neumayer C, Wojta J, Klinger M, Nanobachvili J, Huk I. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue. Eur J Vasc Endovasc Surg. 2015 May;49(5):549-55. doi: 10.1016/j.ejvs.2015.02.011. Epub 2015 Mar 21.</citation>
    <PMID>25800096</PMID>
  </reference>
  <reference>
    <citation>Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, Chin JT, Raaz U, Schoelmerich AM, Raiesdana A, Leeper NJ, McConnell MV, Dalman RL, Spin JM, Tsao PS. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 2012 Feb;122(2):497-506. doi: 10.1172/JCI61598. Epub 2012 Jan 24.</citation>
    <PMID>22269326</PMID>
  </reference>
  <reference>
    <citation>Adam M, Raaz U, Spin JM, Tsao PS. MicroRNAs in Abdominal Aortic Aneurysm. Curr Vasc Pharmacol. 2015;13(3):280-90. Review.</citation>
    <PMID>23713862</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cantanzaro</investigator_affiliation>
    <investigator_full_name>Prof. Raffaele Serra, MD, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Vascular Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

